Tango Therapeutics, Inc.
TNGX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$23.34
KIRA · Stoqly’s AI analyst, in plain words
- Tango Therapeutics, Inc. had $62.4M of revenue in fiscal 2025, up 48.3% on the year before. Over five years, revenue changed +52.1% a year on average.
- Its operating margin was −178.4%, up 167.7 pts: of every 100 in sales, about −178 is left after running the business.
- Tango Therapeutics, Inc. lost $102M in fiscal 2025.
- Free cash flow was −$140M in fiscal 2025, −224.3% of revenue.
Market cap
$3.5B
P/E
—
Revenue
$62.4M
Net income
−$102M
Free cash flow
−$140M
Operating margin
−178.4%
Tango Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+48.3%
Yes. Sales grew 48.3% last year.
Does it make a profit?
−162.9%
No. It lost money last year.
Does profit turn into cash?
−224.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Tango Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Tango Therapeutics, Inc.
- CIK
- 0001819133
Tango Therapeutics, Inc. · TNGX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $37.0M | $24.9M | $36.5M | $42.1M | $62.4M |
| Revenue growth | 383.8% | −32.9% | 46.9% | 15.2% | 48.3% |
| Net interest income | $0.5M | $1.5M | $6.6M | $7.9M | $5.6M |
| Operating margin | −157.1% | −446.8% | −312.6% | −346.1% | −178.4% |
| Net income | −$58.2M | −$108M | −$102M | −$130M | −$102M |
| Net margin | −157.2% | −435.1% | −278.5% | −309.7% | −162.9% |
| Diluted EPS | −$0.94 | −$1.23 | −$1.08 | −$1.19 | −$0.87 |
| Cash | |||||
| Cash from operations | −$59.5M | −$109M | −$118M | −$132M | −$139M |
| Capital expenditure | $1.8M | $7.7M | $1.5M | $0.8M | $1.0M |
| Free cash flow | −$61.4M | −$117M | −$120M | −$132M | −$140M |
| FCF margin | −165.7% | −469.7% | −327.2% | −314.4% | −224.3% |
| Share count change | 94.5% | 41.4% | 7.7% | 15.5% | 6.4% |
| Debt and strength | |||||
| Cash and short-term investments | $485M | $366M | $337M | $258M | $343M |
| Shareholders' equity | $345M | $249M | $253M | $200M | $346M |
| Current ratio | 12.1x | 6.8x | 7.5x | 7.0x | 16.3x |
| Returns and quality | |||||
| Return on equity | −30.4% | −36.4% | −40.5% | −57.6% | −37.2% |
| Return on tangible equity | −16.9% | −43.4% | −40.2% | −65.3% | −29.3% |
| Piotroski F-score | 3 | 0 | 2 | 1 | 3 |
| Altman Z'' | 6.4 | 2.5 | 1.8 | −1.7 | 5.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$7.7M
4 insiders
Of sales under plans
91%
$7.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Tango Therapeutics, Inc. · TNGX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $23.34 a share, the company is worth $3.5B.
Source: SEC EDGAR XBRL filings (CIK 0001819133). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.